Analysts Set CorMedix Inc (NASDAQ:CRMD) PT at $14.86

Shares of CorMedix Inc (NASDAQ:CRMD) have been assigned a consensus recommendation of “Moderate Buy” from the eight research firms that are covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $15.00.

Several research firms have recently commented on CRMD. Weiss Ratings restated a “hold (c)” rating on shares of CorMedix in a research note on Tuesday, August 11th. Zacks Research upgraded CorMedix from a “strong sell” rating to a “hold” rating in a research report on Friday, May 15th. D. Boral Capital reissued a “buy” rating and set a $14.00 price target on shares of CorMedix in a report on Monday, April 27th. Needham & Company LLC upped their price target on CorMedix from $14.00 to $15.00 and gave the stock a “buy” rating in a research report on Monday, April 27th. Finally, Citizens Jmp reaffirmed a “market outperform” rating and issued a $19.00 price objective on shares of CorMedix in a research note on Tuesday, April 28th.

CorMedix Stock Performance

CRMD opened at $8.17 on Friday. The company has a current ratio of 2.56, a quick ratio of 2.36 and a debt-to-equity ratio of 0.31. The company has a market cap of $636.80 million, a price-to-earnings ratio of 3.82 and a beta of 1.50. The company’s 50 day moving average is $8.11 and its 200 day moving average is $7.65. CorMedix has a 12-month low of $6.13 and a 12-month high of $14.96.

CorMedix (NASDAQ:CRMD) last announced its earnings results on Thursday, August 13th. The company reported $0.29 EPS for the quarter, beating analysts’ consensus estimates of $0.24 by $0.05. CorMedix had a net margin of 40.49% and a return on equity of 40.52%. The business had revenue of $101.93 million during the quarter, compared to analysts’ expectations of $96.04 million. On average, equities research analysts predict that CorMedix will post 0.54 EPS for the current year.

Key Headlines Impacting CorMedix

Here are the key news stories impacting CorMedix this week:

• Positive Sentiment: Higher long-term earnings forecasts: HC Wainwright raised its FY2027 EPS estimate to $0.14 from $0.01 and its FY2028 estimate to $0.54 from $0.39. The upgrades suggest stronger expectations for CorMedix’s revenue growth and operating leverage. CorMedix FY2026 EPS Forecast Boosted by HC Wainwright
• Positive Sentiment: Price target increased: Analysts raised CorMedix’s price target to $14.00, implying substantial upside from recent trading levels and reinforcing the bullish sentiment behind the stock’s advance. CorMedix Price Target Raised to $14.00
• Positive Sentiment: FY2026 outlook improved: A separate report said HC Wainwright boosted its FY2026 EPS forecast, supporting the view that CorMedix’s commercial performance may be progressing better than previously expected. CorMedix FY2026 EPS Forecast Boosted by HC Wainwright
• Neutral Sentiment: Near-term estimates remain mixed: HC Wainwright raised its Q3 2026 EPS forecast to a loss of $0.05 from a loss of $0.08, but lowered its Q4 forecast to a loss of $0.08 from a loss of $0.06. This indicates improving expectations for one quarter but continued short-term losses.
• Neutral Sentiment: 2027 is the key test: An analysis described CorMedix’s commercial foundation as durable but cautioned that 2027 will be important for proving sustained growth and profitability. CorMedix: Durable Commercial Base, But 2027 Is The Real Test

Institutional Investors Weigh In On CorMedix

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new position in shares of CorMedix during the 2nd quarter valued at $49,644,000. Deerfield Management Company L.P. bought a new position in CorMedix in the 3rd quarter worth $38,656,000. Marshall Wace LLP increased its stake in CorMedix by 34.6% in the 3rd quarter. Marshall Wace LLP now owns 3,473,494 shares of the company’s stock worth $40,397,000 after buying an additional 893,518 shares in the last quarter. UBS Group AG raised its holdings in CorMedix by 295.3% during the third quarter. UBS Group AG now owns 1,090,908 shares of the company’s stock valued at $12,687,000 after acquiring an additional 814,964 shares during the period. Finally, Jump Financial LLC bought a new stake in CorMedix during the third quarter valued at about $9,003,000. 34.18% of the stock is owned by hedge funds and other institutional investors.

CorMedix Company Profile

CorMedix Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company’s lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers.

In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures.